These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1615579)

  • 21. Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth.
    Hautmann SH; Huland E; Huland H
    Anticancer Res; 1999; 19(4A):2661-3. PubMed ID: 10470215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
    English HF; Heitjan DF; Lancaster S; Santen RJ
    Cancer Res; 1991 Apr; 51(7):1760-5. PubMed ID: 2004359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth of Dunning transplantable prostate adenocarcinomas in rats fed diets with various fat contents.
    Clinton SK; Palmer SS; Spriggs CE; Visek WJ
    J Nutr; 1988 Jul; 118(7):908-14. PubMed ID: 3392600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal testosterone concentration for the treatment of prostatic cancer.
    Trachtenberg J
    J Urol; 1985 May; 133(5):888-90. PubMed ID: 3989932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intratumoral depot interleukin-2 therapy inhibits tumor growth in Dunning adenocarcinoma of the prostate implanted subcutaneously in rats.
    Hautmann S; Huland E; Huland H
    J Cancer Res Clin Oncol; 1997; 123(11-12):614-8. PubMed ID: 9620219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coordinate loss of growth regulatory factors following castration of rats carrying the Dunning R3327 G prostatic tumor.
    Rubenstein M; Shaw M; Targonski P; McKiel CF; Dubin A; Guinan PD
    Clin Physiol Biochem; 1992; 9(2):47-50. PubMed ID: 1284786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dunning R3327-G prostate carcinoma of the rat: an appropriate model for drug evaluation.
    Kager M; Spruss T; Schneider MR; von Angerer E
    J Cancer Res Clin Oncol; 1992; 118(5):334-8. PubMed ID: 1583064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Central nervous system-mediated growth inhibition of a rat prostate carcinoma by an opioid.
    Reubi JC
    J Endocrinol; 1985 Nov; 107(2):247-50. PubMed ID: 4067481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor.
    Rubenstein M; Shaw M; Targonski P; McKiel CF; Dubin A; Guinan P
    Urol Res; 1991; 19(5):309-12. PubMed ID: 1949430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen treatment combined with castration inhibits tumor growth more effectively than castration alone in the Dunning R3327 rat prostatic adenocarcinoma.
    Landström M; Bergh A; Tomic R; Damber JE
    Prostate; 1990; 17(1):57-68. PubMed ID: 1696714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of prolactin on rat dorsolateral prostate and R3327 prostatic tumor sublines.
    Johnson MP; Thompson SA; Lubaroff DM
    J Urol; 1985 Jun; 133(6):1112-20. PubMed ID: 4039764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An inhibitory effect of TZP-4238 on the growth of androgen-sensitive rat prostatic tumor (Dunning R3327).
    Ichikawa T; Akimoto S; Shimazaki J
    Endocr J; 1993 Aug; 40(4):425-30. PubMed ID: 7522799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.
    Ellis WJ; Isaacs JT
    Cancer Res; 1985 Dec; 45(12 Pt 1):6041-50. PubMed ID: 4063963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations of physical and biochemical parameters of the R3327-CP rat prostate adenocarcinoma following hormonal manipulation of the host.
    Buttyan R; Tomashefsky P; Deitch AD; Olsson CA; Devere-White R
    J Urol; 1984 Jun; 131(6):1218-24. PubMed ID: 6726931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proliferative response of the Dunning R3327H experimental model of prostatic adenocarcinoma to conditions of androgen depletion and repletion.
    English HF; Kloszewski ED; Valentine EG; Santen RJ
    Cancer Res; 1986 Feb; 46(2):839-44. PubMed ID: 3940646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen stimulated chemotherapy in the Dunning R-3327 prostatic adenocarcinoma.
    Grossman HB; Kleinert EL; Lesser ML; Herr HW; Whitmore WF
    Urol Res; 1981; 9(5):237-40. PubMed ID: 7303347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
    Tomura A; Kuroiwa S; Okada M; Abe F
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats.
    Van Ginckel R; De Coster R; Wouters W; Vanherck W; van der Veer R; Goeminne N; Jagers E; Van Cauteren H; Wouters L; Distelmans W
    Prostate; 1990; 16(4):313-23. PubMed ID: 2371176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the preestrogen 4-androstene-3,17-dion-19-al on the Dunning R3327 prostatic adenocarcinoma.
    Marks TA; Petrow V
    Cancer Res; 1983 Aug; 43(8):3687-90. PubMed ID: 6861138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of castration, testosterone and oestrogen on epithelial and stromal growth and morphology of the Dunning (R3327H) prostatic adenocarcinoma.
    Damber JE; Landström M; Bergh A; Tomic R
    Scand J Urol Nephrol Suppl; 1988; 110():145-8. PubMed ID: 3187402
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.